Abstract
Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT). Monitoring of EBV DNA in high-risk patients with subsequent pre-emptive rituximab treatment is highly effective, and can prevent EBV-associated disease following HSCT. Here, we report a 10-year-old girl with aplastic anemia who developed CD20 negative EBV-PTLD after unrelated bone marrow transplantation that was refractory to rituximab treatment. Similar to other types of lymphoma, the absence of CD20 antigen is likely to be characteristic of rituximab-refractory EBV-PTLD.
Original language | English |
---|---|
Pages (from-to) | 779-781 |
Number of pages | 3 |
Journal | International journal of hematology |
Volume | 93 |
Issue number | 6 |
DOIs | |
Publication status | Published - Jun 2011 |
Externally published | Yes |
Keywords
- Aplastic anemia
- CD20
- Epstein-Barr virus
- Post-transplant lymphoproliferative disease
- Rituximab
- Unrelated bone marrow transplantation
ASJC Scopus subject areas
- Hematology